Latest Technology Platform News

Firebird Metals has locked in exclusive global rights to key LMFP patents through 2045 and commissioned lithium-manganese-rich cathode equipment, progressing its Australian Demonstration Plant with a $2 million ARENA grant.

Adisyn has confirmed a major graphene breakthrough compatible with semiconductor manufacturing and secured exclusive radar absorption rights, backed by a $14 million placement led by top institutional investors.

Ovanti Limited is issuing a bonus tranche of Loyalty Options to shareholders at no cost, exercisable at a modest $0.025, potentially raising close to $1 million if fully converted.

Adisyn Ltd has landed a A$14 million placement led by heavyweight institutional investors following two major graphene technology milestones in semiconductors and stealth drone materials.

Noxopharm reports preclinical data revealing SOF-SKN’s active ingredient remains in skin tissues for about 3.5 days with minimal systemic absorption, supporting less frequent dosing and sustained activity for cutaneous lupus treatment.

Invion Limited is broadening its non-melanoma skin cancer trial to include basal cell carcinoma patients following encouraging safety and efficacy data from squamous cell carcinoma cohorts, targeting the largest skin cancer segment.

MA Financial Group reported a 44% year-on-year jump in assets under management to $14.8 billion in 1Q26, underpinned by strong lending growth and transactional activity despite asset sales and market volatility.

Pantera Minerals has seen a 37% uplift in the valuation of its EnergyX stake following an increase in EnergyX’s Regulation A raise price to US$13 per share, reflecting operational progress and stronger market confidence.

Calix Limited has secured an initial A$5.7 million payment following the completion of its lithium Mid-Stream Project restructure with PLS Group, releasing $11.4 million in capital and shifting to a capital-light licensing model.

Noxopharm appoints its Chief Scientific Officer Dr Olivier Laczka as CEO, aiming to capitalise on recent clinical successes and expand the Sofra™ technology’s reach in autoimmune and oncology markets.

Mesoblast has acquired exclusive rights to a patented chimeric antigen receptor platform designed to enhance the targeting and potency of its mesenchymal stromal cell therapies, aiming to expand treatment options for inflammatory and autoimmune diseases.

ReadCloud Limited posted a record $5.2 million in quarterly cash receipts for Q2 FY26, driven by surging demand in its school-focused ReadCloudVET and eBooks divisions. The company now serves 440 schools and is on track to meet its FY26 financial targets without raising capital.